Home/Pipeline/Rapid Antimicrobial Susceptibility Testing (AST)

Rapid Antimicrobial Susceptibility Testing (AST)

Rapid phenotypic AST based on fluorescent detection of bacterial growth

CommercialActive

Key Facts

Indication
Rapid phenotypic AST based on fluorescent detection of bacterial growth
Phase
Commercial
Status
Active
Company

About Molsid

Molsid is a private, innovative biotech/medtech company addressing the critical global challenge of antimicrobial resistance (AMR) through rapid diagnostics. Its core technology is the SmartID® platform of fluorogenic biotracers, which enable the detection of specific bacterial enzyme activity, such as beta-lactamases, directly from primary clinical samples in as little as two hours. The company has two main product lines: 'Early Warning Beta-lactamases Detection' tests and 'Rapid Antimicrobial Susceptibility Testing' (AST) kits, positioning it in the growing market for rapid, actionable infectious disease diagnostics.

View full company profile

Therapeutic Areas